Roche’s PI3K inhibitor Itovebi (inavolisib) has been approved by the US Food and Drug Administration (FDA) as part of a ...

Keytruda (pembrolizumab) and Astellas/Pfizer’s Padcev (enfortumab vedotin) have been approved by the Medicines and Healthcare ...

Eli Lilly has partnered with insitro to advance new treatments for metabolic diseases, including metabolic ...

Merck & Co – known as MSD outside the US and Canada – has entered into a licence and research collaboration agreement worth ...

Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been ...

AstraZeneca (AZ) has entered into an exclusive licence agreement worth over $1.9bn to advance CSPC Pharmaceutical Group’s pre-clinical lipid-lowering therapy, strengthening the Anglo-Swedish drugmaker ...

AbbVie has shared positive top-line results from a late-stage study of its investigational Parkinson’s disease (PD) drug in adults. The phase 3 TEMPO-1 trial evaluated two fixed doses of the D1/D5 ...

Research on the state of the customer experience (CX) that the global pharmaceutical industry provides to healthcare professionals (HCPs) has been released by DT Consulting, an Indegene company. For ...

Johnson & Johnson (J&J) has announced results from a real-world study comparing its Erleada (apalutamide) to Pfizer and Astellas’ Xtandi (enzalutamide) in patients with metastatic castration-sensitive ...

Chiesi Group has announced the operational launch of its biotech centre of excellence in Italy. The company has invested €400m to establish the facility, which it said is dedicated to developing and ...

It is hoped that preventing healthy cells from reading the molecules’ messages could lead to safer and more effective gene therapies for MND, as well as other neurodegenerative diseases, including ...